| abstract |
The invention relates to transposon Hsmar2 and to the use thereof in the generation of vectors that can be used in somatic gene therapy. The invention also relates to the generation of the first active human DNA transposon, Hsmar2, as well as an analysis of the activity thereof in mammal cells and, in particular, human cells. More specifically, the invention relates to the functional characterisation of Hsmar2 and the ability thereof to transpose DNA fragments flanked by TR-Hsmar2 sequences from a donor genome to a recipient genome. |